Sparsh Bio-tech Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sparsh Bio-tech Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $17.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sparsh Bio-tech Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $17.0M Trade | TransData Nexus

Sparsh Bio-tech Private Limited

Indian Pharmaceutical Exporter · Antibiotics Specialist · $17.0M Total Trade · DGFT Verified

Sparsh Bio-tech Private Limited is an Indian pharmaceutical exporter with a total trade value of $17.0M across 2 products in 1 therapeutic categories. Based on 392 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ampicillin ($10.4M), Amoxicillin ($6.5M), .

Sparsh Bio-tech Private Limited — Export Portfolio & Destination Treemap

Sparsh Bio-tech Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sparsh Bio-tech Private Limited? — Company Overview & Market Position

Sparsh Bio-Tech Private Limited, established on March 30, 2001, is a privately held pharmaceutical company headquartered in Jamnagar, Gujarat, India. The company specializes in the manufacturing of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Its Corporate Identification Number (CIN) is U24231GJ2001PTC039373. As of the latest available data, Sparsh Bio-Tech has an authorized capital of ₹5.00 crore and a paid-up capital of ₹3.35 crore. The company employs approximately 104 professionals. The registered office is located at Plot No.1, Survey No. 242/243/244, Village Lakhabavad, Post Khodiyar Colony, District Jamnagar, Gujarat, 361006.

What Does Sparsh Bio-tech Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ampicillin$10.4M 2Amoxicillin$6.5M

Sparsh Bio-tech Private Limited Therapeutic Categories — 1 Specializations

Product Portfolio — Top 2 by Export Value

Sparsh Bio-tech Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ampicillin	Antibiotics	$10.4M	209	7.3%	3
2	Amoxicillin	Antibiotics	$6.5M	183	1.1%	11

Sparsh Bio-tech Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $17.0M. The top category is Antibiotics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sparsh Bio-tech Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sparsh Bio-Tech operates a dedicated beta-lactam unit in Jamnagar, Gujarat, India. This facility is WHO-GMP certified and specializes in the production of finished pharmaceutical formulations, including tablets, capsules, and dry syrups. The plant is an export-oriented unit, supplying products to various countries such as Uganda, Rwanda, Kenya, Congo, Tanzania, Zambia, Guyana, Cambodia, Burundi, Ghana, and Madagascar.

3Key Leadership

The leadership team at Sparsh Bio-Tech includes:

Ashok Juthalal Maru: Managing Director since March 30, 2001.

Paras Juthalal Maru: Whole-Time Director since April 1, 2003.

Sundeep Premchand Maru: Whole-Time Director since September 30, 2005.

Rasik Hirji Haria: Director since November 3, 2001.

These individuals have been instrumental in steering the company's strategic direction and operational growth.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sparsh Bio-tech Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sparsh Bio-Tech's export portfolio is concentrated in the antibiotic segment, with a total export value of $17.0 million USD across 392 shipments. The primary products exported are Ampicillin ($10.4 million, 7.3% market share) and Amoxicillin ($6.5 million, 1.1% market share), both of which are finished pharmaceutical formulations. The company's focus on these products indicates a strategic emphasis on the antibiotic therapeutic category. While specific regulatory approvals in the US, EU, UK, Australia, and Japan are not detailed in the available data, the company's export activities to various countries suggest compliance with international regulatory standards.

2Emerging Markets

Sparsh Bio-Tech has established a presence in several emerging markets, including countries in Africa (Uganda, Rwanda, Kenya, Congo, Tanzania, Zambia, Ghana, Madagascar), Latin America (Guyana), and Southeast Asia (Cambodia, Burundi). The company's WHO-GMP certification for its manufacturing facility enhances its credibility and facilitates access to these markets. This certification is recognized by the World Health Organization and is a prerequisite for supplying pharmaceutical products to many countries.

3Geographic Strategy

Sparsh Bio-tech Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

The available data does not provide specific information regarding Sparsh Bio-Tech's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. This lack of information suggests that the company may not currently have FDA approvals for its products. For importers in the United States, it is crucial to verify the regulatory status of Sparsh Bio-Tech's products to ensure compliance with FDA requirements.

2WHO & EU GMP

Sparsh Bio-Tech's manufacturing facility holds WHO-GMP certification, indicating adherence to international quality standards. However, there is no specific information available regarding EU GMP certification or EDQM status. Importers in the European Union should verify the company's compliance with EU GMP standards to ensure product quality and regulatory acceptance.

3CDSCO & Indian Regulatory

The available data does not detail Sparsh Bio-Tech's compliance with the Central Drugs Standard Control Organisation (CDSCO) regulations, state drug controller approvals, or export No Objection Certificates (NOCs). Importers should conduct due diligence to confirm the company's adherence to Indian regulatory requirements, which is essential for ensuring the legality and safety of the products.

Sparsh Bio-tech Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sparsh Bio-Tech operates in the competitive antibiotic segment, with its top products being Ampicillin and Amoxicillin. The company's market share in these products is 7.3% and 1.1%, respectively. While specific competitors are not identified in the available data, the antibiotic market is typically characterized by numerous players, including both large multinational corporations and regional manufacturers. Sparsh Bio-Tech's focus on finished formulations and export-oriented strategy positions it to compete effectively in these markets.

2Key Differentiators

Sparsh Bio-Tech's key differentiators include its WHO-GMP certified manufacturing facility, which ensures adherence to international quality standards, and its specialization in beta-lactam antibiotics. The company's export-oriented approach and focus on finished pharmaceutical formulations allow it to cater to a diverse clientele in emerging markets. These strengths contribute to its competitive advantage in the pharmaceutical export sector.

3Strategic Position

Sparsh Bio-Tech's current strategic direction centers on the production and export of finished pharmaceutical formulations, particularly beta-lactam antibiotics. The company's WHO-GMP certification and export activities indicate a commitment to quality and international market expansion. Future strategic initiatives could involve diversifying its product portfolio, expanding into new geographic regions, and obtaining additional regulatory approvals to enhance its global presence and competitiveness.

Buyer Due Diligence Brief — Evaluating Sparsh Bio-tech Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sparsh Bio-Tech has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $17.0 million USD across 392 shipments. The company's focus on finished pharmaceutical formulations and its WHO-GMP certified manufacturing facility underscore its commitment to quality and reliability. Importers should assess the company's compliance with relevant regulatory standards and verify the quality of its products to ensure a reliable supply chain.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

WHO-GMP Certification: Confirms adherence to international manufacturing standards.

EU GMP Certification: Ensures compliance with European Union manufacturing standards.

FDA Approval: Validates that products meet U.S. Food and Drug Administration requirements.

Frequently Asked Questions — Sparsh Bio-tech Private Limited

How many pharmaceutical products does Sparsh Bio-tech Private Limited export from India?

Sparsh Bio-tech Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Ampicillin ($10.4M), Amoxicillin ($6.5M). Total export value is $17.0M.

What is Sparsh Bio-tech Private Limited's total pharmaceutical export value?

Sparsh Bio-tech Private Limited's total pharmaceutical export value is $17.0M, based on 392 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Sparsh Bio-tech Private Limited cover?

Sparsh Bio-tech Private Limited exports across 1 therapeutic categories. The largest are Antibiotics (100.0%, 2 products).

Get Full Sparsh Bio-tech Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.